Atlas Trials

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.

Clinical trial NCT05181462 · COMPLETED

Trial details

NCT number
NCT05181462
Sponsor
Cantargia AB
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2022-01-11
Primary completion
2026-04-09
Enrollment
117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.